Tracey E Schefter
Overview
Explore the profile of Tracey E Schefter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santoso A, Vinogradskiy Y, Robin T, Goodman K, Schefter T, Miften M, et al.
Adv Radiat Oncol
. 2024 Feb;
9(3):101409.
PMID: 38298328
Purpose: Positional errors resulting from motion are a principal challenge across all disease sites in radiation therapy. This is particularly pertinent when treating lesions in the liver with stereotactic body...
2.
Hallemeier C, Moughan J, Haddock M, Herskovic A, Minsky B, Suntharalingam M, et al.
JAMA Netw Open
. 2023 Apr;
6(4):e238504.
PMID: 37083668
Importance: For many types of epithelial malignant neoplasms that are treated with definitive radiotherapy (RT), treatment prolongation and interruptions have an adverse effect on outcomes. Objective: To analyze the association...
3.
Fakhoury K, Schubert L, Coyne M, Aldridge W, Zeiler S, Stuhr K, et al.
Cureus
. 2023 Feb;
14(12):e33100.
PMID: 36721584
The purpose of this report is to present the implementation of a process for after-hours radiation treatment (RT) utilizing remote treatment planning based on optimized diagnostic computed tomography (CT) scans...
4.
Kharofa J, Yothers G, Kachnic L, Ajani J, Meyer J, Augspurger M, et al.
Am J Clin Oncol
. 2022 Nov;
45(12):534-536.
PMID: 36413683
Novel toxicity metrics that account for all adverse event (AE) grades and the frequency of may enhance toxicity reporting in clinical trials. The Toxicity Index (TI) accounts for all AE...
5.
Kachnic L, Winter K, Myerson R, Goodyear M, Abitbol A, Streeter O, et al.
Int J Radiat Oncol Biol Phys
. 2021 Aug;
112(1):146-157.
PMID: 34400269
Purpose: A multi-institutional phase 2 trial assessed long-term outcomes of dose-painted intensity modulated radiation therapy (IMRT) with 5-fluorouracil (5FU) and mitomycin-C (MMC) for anal canal cancer. Methods And Materials: T2-4N0-3M0...
6.
Rahma O, Yothers G, Hong T, Russell M, You Y, Parker W, et al.
JAMA Oncol
. 2021 Jul;
7(8):1225-1230.
PMID: 34196693
Importance: Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As...
7.
Machicado J, Obuch J, Goodman K, Schefter T, Frakes J, Hoffe S, et al.
Clin Gastroenterol Hepatol
. 2019 May;
17(13):2749-2758.e2.
PMID: 31042578
Background & Aims: Fiducial markers are inert radiopaque gold or carbon markers implanted in or near pancreatic tumor to demarcate areas for image-guided radiation therapy. Endoscopic ultrasound (EUS) pre-loaded fiducial...
8.
Olsen J, Schefter T
Int J Radiat Oncol Biol Phys
. 2019 Apr;
102(5):1406.
PMID: 31014784
No abstract available.
9.
Ladbury C, Goodman K, Schefter T, Olsen J
Semin Radiat Oncol
. 2019 Mar;
29(2):137-143.
PMID: 30827451
Since the initial development of 5-fluorouracil and mitomycin as a standard of care platform for definitive anal cancer chemoradiotherapy, multiple studies have evaluated the optimal chemotherapy regimen, and radiotherapy technique....
10.
Dewberry L, Wingrove L, Marsh M, Glode A, Schefter T, Leong S, et al.
J Surg Res
. 2019 Jan;
235:66-72.
PMID: 30691852
Background: Locally advanced esophageal cancer is often treated with neoadjuvant therapy followed by surgery. Many patients present with or experience clinical deconditioning during neoadjuvant therapy. Prehabilitation programs in other areas...